Tsoi Hoi Shan. [Photo by Wen Bo]

Looking out from his office in Tanzhou Town, Zhongshan City, Tsoi Hoi Shan, Chairman of the United Laboratories International Holdings Limited (TUL), can see 2 open spaces behind the factory. In the near future, a modern intelligent logistics center and a small-molecule chemical medicine research and development building will settle here.

This factory was the first set up by his father, Kam Lok Choy, who returned to the Mainland of China with the aim of "serving the motherland". It was also the place where Tsoi Hoi Shan's dream began after he completed his studies.

Kam Lok Choy's ancestral home was Jieyang in Guangdong Province. He started his career in Hong Kong and has been involved in garment manufacturing and other industries. In the early 1990s, Kam Lok Choy visited the Pearl River Delta and invested in the first factory in Tanzhou Town. The factory witnessed the city's urbanization in the past over 20 years.

In recent years, TUL has been fighting for a place in the field of diabetic biopharmaceuticals, which is monopolized by foreign drugs.

In terms of industrial chain, TUL has the R&D, production and sales capacity of pharmaceutical preparations, raw materials and intermediates, 6 production bases and 4 R&D centers, thereby becoming a comprehensive pharmaceutical group integrating R&D, production and operation.

TUL ranked 22nd in the "2018 China's Top 100 Pharmaceutical Companies" released by the China National Pharmaceutical Industry Information Center.

During the first half of 2019, TUL saw an operating income of 4.09 billion yuan and a net profit of nearly 300 million yuan. Its net profit increased by 224.6% year-on-year. The company invested 119 million yuan in research and development, up by 19% year-on-year.

Tsoi Hoi Shan said that, relying on the independent innovation of the platform and horizontal cooperation with renowned research and development institutions at home and abroad, TUL is establishing a number of new drug research and development projects, covering such cutting-edge areas as anti-infective drugs, anti-tumor drugs, respiratory drugs, diabetes drugs, cardiovascular and cerebrovascular drugs, and anti-Alzheimer's drugs.

TUL also takes active part in public service, meaning giving back to the community. "Entrepreneurship, in my view, is about innovation on the one hand and social responsibility on the other. Continuous innovation, honest management and active assumption of social responsibility help us to step up to a new level in the pharmaceutical revolution," Tsoi Hoi Shan concluded.